This guide provides mental health decision-makers (e.g., state/local mental health directors, treatment facility clinical directors, and other stakeholders) with rationale and evidence to support wide-spread expansion of Cognitive Behavioral Therapy for Psychosis (CBTp) across mental health systems.

This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

This Advisory can help clinicians who work in a mental health facility implement a tobacco cessation program to reduce the use of tobacco-related products and tobacco-related diseases among clients with SMI.

This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.